ADHD in the News 2024-02-01
ADHD medication recalled: FDA says bottles might have the wrong pills in them
A pharmaceutical company is recalling medication for ADHD (attention deficit hyperactivity disorder) and narcolepsy because packages of the drug may contain the wrong pills, the U.S. Food and Drug Administration is reporting.
In utero stimulant exposure not tied to later neurodevelopmental issues
Amphetamine/dextroamphetamine and methylphenidate exposure in utero does not appear to increase the risk for childhood neurodevelopmental disorders, according to a study published online Jan. 24 in JAMA Psychiatry.
‘A term for babies’: Researcher explains how some TikTokers misunderstand clinical terms
A University of British Columbia report found that more than half of the 100 most popular videos on TikTok about the neurodevelopmental disorder ADHD contained misleading information. Dr. Anthony Yeung, who led the research, explains why ADHD self-diagnosis could be dangerous.
Distracted, Forgetful and Hooked on Smartphones: Why More Women Are Being Diagnosed With ADHD
Diagnoses of ADHD are surging in a surprising group: adult women. Doctors who treat them are looking at smartphones as both a contributor and a cure.
OHSU researchers confirm cumulative, brain-wide effects of ADHD
Researchers at Oregon Health & Science University and the University of Minnesota Masonic Institute for the Developing Brain leveraged a large national dataset and neuroimaging to confirm the brain-wide effects of attention-deficit hyperactivity disorder, or ADHD. The study, published today in the Journal of Neuroscience, further unravels the complex relationship between brain connectivity and behavioral disorders.
Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD
A recent study confirmed using substances such as alcohol, cannabis, and nicotine, is linked to worsened psychiatric symptoms in adolescents. [1],[2] The research ultimately disproved that substances have unique or nonunique associations with psychiatric symptoms—a single substance type was not linked to a particular psychiatric disorder.
Late Breaking News From APSARD 2024 Conference
CONFERENCE REPORTER: Last week, the American Professional Society for ADHD and Related Disorder’s 2024 conference brought together the nation’s top researchers, educators, and clinicians in conjunction with key governmental stakeholders, including the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).
ADHD testing for children, young adults is being offered in Florida. Here’s what to know
Attention Deficit Hyperactivity Disorder or ADHD is one of the most common diagnoses in children. But now, the country’s largest pediatric urgent care network is offering testing. NBC6’s Sheli Muñiz has more.
Prescription Rates Spiked During The Pandemic–Why? (Science Friday, January 26, 2024)
The rate of prescriptions for ADHD medications rose by 30% during the height of the pandemic, from 2020 to 2022. Most of these new prescriptions were given to people between the ages of 20 and 39. And the prescription rate for those assigned female at birth, including women and some trans people, doubled during this time as well, according to a recent study. Prescriptions for anxiety and depression medications did not rise at a similarly high rate during that time.
ADHD Tax: What It Is and How to Avoid It
If you have ADHD, managing money may be difficult. Adopting these strategies can help.
What Comes After an Adult ADHD Diagnosis?
KEY POINTS: Psychoeducation is commonly offered to help shed light on the effects of ADHD and treatment options. A recent review study examined the characteristics of existing psychoeducational programs for adult ADHD. Psychoeducation personalized to the needs of individuals is part of the adult ADHD treatment process.
Second-Generation Monarch eTNS System Cleared for Pediatric ADHD
The Food and Drug Administration (FDA) has cleared NeuroSigma’s second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) System for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients 7 to 12 years of age who are not being treated with ADHD medications.